文献速递免疫规划传染病防控与疫情报告

5至11岁儿童接种BNT162b2(辉瑞-BioNTech)SARS-CoV-2疫苗的短期安全性:一项全国性家长调查

Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey.
PubMed 文献 · Vaccine · 2024-01-27

该研究在以色列一家大型健康维护组织中,向5至11岁儿童接种BNT162b2疫苗后的家长发放电子问卷调查短期不良反应。第一剂与第二剂调查分别回收5,842份和6,126份,应答率分别为32.1%和24.8%;局部不良反应报告率分别为68.7%和69.1%,全身不良反应分别为20.8%和34.5%,多数症状持续不超过3天,92%的受访者报告孩子接种后无需就医。作者认为结果进一步支持该疫苗在5至11岁儿童中的短期安全性。

要点

  • 第一剂与第二剂局部不良反应报告率分别为68.7%与69.1%,全身不良反应分别为20.8%与34.5%。
  • 最常见症状为乏力、头痛和肌痛;症状持续3天及以内者分别占第一剂86.5%、第二剂81.5%。
  • 92%的受访者报告孩子接种后无需任何就医咨询。

核心结论

  • 作者认为研究结果进一步支持BNT162b2 SARS-CoV-2疫苗在5至11岁儿童中的短期安全性,并可在疫情持续及未来加强针接种时增强家长和接种人员的疫苗信心。

研究设计与样本

  • 观察性横断面研究,通过电子问卷在儿童接种BNT162b2疫苗后一周发送给家长,调查机构为以色列一家大型健康维护组织。
  • 第一剂调查回收5,842份、第二剂调查回收6,126份,应答率分别为32.1%和24.8%。

主要发现

  • 局部不良反应报告率第一剂为68.7%、第二剂为69.1%;全身不良反应报告率第一剂为20.8%、第二剂为34.5%。
  • 最常报告的症状为乏力、头痛和肌痛。
  • 症状持续3天及以内者占第一剂受访者的86.5%、第二剂受访者的81.5%。
  • 92%的受访者报告孩子接种后无需任何就医咨询。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: SARS-CoV-2 vaccine safety is of major interest worldwide, and transparent information about potential side effects is essential to decrease vaccine hesitancy. The aim of this study was to assess SARS-CoV-2 BNT162b2 vaccine short-term side effects among children aged 5-11 years. METHODS: An observational, cross sectional study of vaccine side-effects using electronic surveys sent to parents one week post administration of BNT162b2 vaccine to their child in a large health maintenance organization in Israel. RESULTS: First dose and second dose surveys were filled for 5,842 and 6,126 children, respectively, with a response rate of 32.1% and 24.8%. Local side effects were reported by 68.7% and 69.1% of the first and second survey respondents, and general side effects were reported by 20.8% and 34.5% of them. The symptoms most frequently reported were fatigue, headache and myalgia. Duration of symptoms lasted three days or less among 86.5% and 81.5% of first and second dose survey respondents. Most respondents (92%) reported that their child did not need any medical consultation following vaccination. CONCLUSIONS: We found further support for the BNT162b2 SARS-CoV-2 vaccine short- term safety among children aged 5-11 years. With ongoing pandemic and future booster COVID-19 vaccines, these findings can encourage vaccine confidence for parents and providers.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shapiro Ben David S, Baruch Gez S, Adler L, et al. Short term safety of BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine among children aged 5-11 years, a nationwide parental survey. Vaccine. 2024. PMID: 38281902. doi:10.1016/j.vaccine.2024.01.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。